Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression

Justine E Marum, PhD, Leanne Purins, PhD, David T Yeung, BSc, MBBS, FRACP, FRCPA, Wendy Tara Parker, PhD, David J Price, PhD, Paul PS Wang, PhD, Doris Stangl, PhD, Jasmina Geogievski, BSc, Bradley Chereda, PhD, Andreas Schreiber, PhD, Simon J Tuke, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Susan Branford, PhDFFSc (RCPA)

Blood (2015) 126 (23): 475.

https://doi.org/10.1182/blood.V126.23.475.475

Published: 2015

Journal Articles

The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2

Laura N Eadie, PhD, Verity A Saunders, BSc (Hons), Tamara M Leclercq, PhD, Susan Branford, PhDFFSc (RCPA), Deborah L White, PhD FFSc (RCPA), Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 4841.

https://doi.org/10.1182/blood.V126.23.4841.4841

Published: 2015

Journal Articles

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Francisco Cervantes, Nelson Spector, MD PhD, Brian Leber, MD, Susan Branford, PhDFFSc (RCPA), Tara A. Glynos, BS, Sandip Acharya, MSc, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 4029.

https://doi.org/10.1182/blood.V126.23.4029.4029

Published: 2015

Journal Articles

High Incidence of Mutated Cancer-Associated Genes at Diagnosis in CML Patients with Early Transformation to Blast Crisis

Susan Branford, PhDFFSc (RCPA), Paul PS Wang, PhD, Wendy Tara Parker, PhD, David Yeung, Justine E Marum, PhD, Doris Stangl, PhD, Zoe Donaldson, Alexandra Yeoman, Nathalie Nataren, Ieuan Walker, Leanne Purins, Bradley Chereda, PhD, Christopher N Hahn, PhD, Hamish S Scott, BSc, PhD FFSc (RCPA), Andreas Schreiber, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 600.

https://doi.org/10.1182/blood.V126.23.600.600

Published: 2015

Journal Articles

BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR

David T Yeung, BSc, MBBS, FRACP, FRCPA, Wendy Tara Parker, PhD, Stuart Phillis, B Biotech, Jasmina Georgievski, BSc, Hamish S Scott, BSc, PhD FFSc (RCPA), Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Susan Branford, PhDFFSc (RCPA)

Blood (2015) 126 (23): 2777.

https://doi.org/10.1182/blood.V126.23.2777.2777

Published: 2015

NARROW

Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression

The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

High Incidence of Mutated Cancer-Associated Genes at Diagnosis in CML Patients with Early Transformation to Blast Crisis

BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR

Email alerts

ASH Publications

American Society of Hematology

Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression

The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

High Incidence of Mutated Cancer-Associated Genes at Diagnosis in CML Patients with Early Transformation to Blast Crisis

BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only